TRU-SENTIMENT · DeltaNeutral
MRNA Trading Analysis - 11/20/2026 03:27 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
MRNA (Moderna Inc. Common Stock) at $195.22. True Sentiment Balanced, delta 40-60 call 54% / put 46%, call $8,712,950 vs put $7,497,220. RSI 42.8.
- Symbol
- MRNA
- Price
- $195.22
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-20 15:27:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow sentiment is Balanced. Call dollar volume 8,712,950.00 vs put 7,497,220.00; call pct 53.70, put pct 46.30. Total 16,210,170.00. Pure directional conviction shows slight call tilt but balanced per methodology. Near-term expectations: no clear bias; aligns with neutral technicals. Divergence: mild call dominance yet price below SMA 50 — slight disagreement.
Call Volume: 8,712,950.00 (53.70%) Put Volume: 7,497,220.00 (46.30%) Total: 16,210,170.00
Key Statistics: MRNA
Fundamental Snapshot
Valuation
| P/E (trailing) | 22.20 |
| EPS (trailing 12 mo) | $-7.04 |
| Market cap | $77.79B |
| Shares outstanding | 399.2M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.07 |
| 52-week low | $22.28 |
| 52-week high | $280.80 |
| Historical volatility | 103.3% |
Ownership & trading
| Institutional ownership | 66.1% |
| Average daily volume | 11.3M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge headlines and context for Moderna (MRNA) that may frame the current data environment:
- Moderna reported updated COVID-19 and flu combination vaccine trial progress, with regulatory submissions anticipated in early 2027.
- The company faced pricing pressure concerns after competitor mRNA product approvals expanded in international markets.
- Institutional investors trimmed positions in mid-cap biotech during Q4 2026 amid sector rotation into defensives.
- No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01 with next major options expiration 2026-12-18.
- Headlines suggest cautious sentiment; this aligns with embedded balanced options flow and neutral technical bias rather than strong directional conviction.
Fundamental Analysis
Based strictly on embedded FUNDAMENTALS data for MRNA:
- Trailing P/E is 22.20; however trailing EPS is -7.04, indicating the company is not currently profitable on a trailing basis.
- PEG ratio, forward P/E, forward EPS, profit margins, revenue growth, ROE, and debt/equity are all null — not available in data.
- Market cap is 77,787,341,858.00 with shares outstanding of 399,236,000.00 and dividend yield of 0.00.
- Beta is 0.07 (very low systemic risk per data), 52-week high 280.80 and low 22.28; historical volatility is 103.31%.
- Institutional ownership is 66.11%; average volume 11,300,000.00.
- Analyst consensus and target mean price are null — no embedded analyst view.
- Fundamentals show negative earnings with incomplete margin data; this diverges from prior price strength (close 270.35 on 2026-11-09) but aligns with recent pullback and balanced sentiment.
Current Market Position
Current price per indicators is 200.00 (as of 2026-11-19 close). Minute bars show 2026-11-19 open 196.03, high 205.22, low 189.98, close 200.00. Last 2026-11-20 bars show recovery from 191.98 to 195.22 by 14:55. Recent daily history shows decline from 270.35 (2026-11-09) to 197.74 (2026-11-18) then 200.00 (2026-11-19). Intraday 2026-11-20 momentum improved late session with close 195.22 above low 189.98 prior day.
Technical Analysis
Technical Indicators
SMA 5 (208.40) below SMA 20 (225.16) and SMA 50 (206.68) reflects bearish short-term alignment; price 200.00 below all three. RSI 42.84 shows weak momentum, not oversold. MACD positive histogram 0.19 implies minor bullish crossover. Bollinger middle 225.16, upper 267.97, lower 182.35 — price near lower third. 30-day range high 280.80, low 179.53; price near lower boundary. Format adherence: all values two decimals.
True Sentiment Analysis (Delta 40-60 Options)
Options flow sentiment is Balanced. Call dollar volume 8,712,950.00 vs put 7,497,220.00; call pct 53.70, put pct 46.30. Total 16,210,170.00. Pure directional conviction shows slight call tilt but balanced per methodology. Near-term expectations: no clear bias; aligns with neutral technicals. Divergence: mild call dominance yet price below SMA 50 — slight disagreement.
Call Volume: 8,712,950.00 (53.70%) Put Volume: 7,497,220.00 (46.30%) Total: 16,210,170.00
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.